Liposomes containing NY-ESO-1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines

Nanomedicine

Volumn 9, Issue 4, 2014, Pages 435-449

  Cruz, Luis J ^a,b   Rueda, Felix ^a   Simón, Lorena ^a,b   Cordobilla, Begoña ^a   Albericio, Fernando ^a,b,c   Domingo, Joan C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

cancer vaccine; delivery system; dendritic cell; immunogenicity; immunotherapeutic vaccines; peptide; peptide vaccines; targeting

Indexed keywords

CANCER VACCINE; FC RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1BETA; LIPOSOME; MULTIPLE ANTIGENIC PEPTIDE INTERFERON GAMMA; NY ESO 1 ANTIGEN; PALMITOYLATED INTERLEUKIN 1BETA; TETANUS TOXOID; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CTAG1B PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; PEPTIDE;

ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; HYBRID; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; NANOENCAPSULATION; PRIORITY JOURNAL; PROTEIN TARGETING; CELL CULTURE; DRUG DELIVERY SYSTEM; IMMUNOLOGY; NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, NEOPLASM; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MEMBRANE PROTEINS; NEOPLASMS; PEPTIDES; RECEPTORS, IGG; TETANUS TOXOID;

EID: 84899836961     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.66     Document Type: Article

References (56)

1. Hutchings C.L. Gilbert S.C. Hill A.V. Moore A.C. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity J Immunol 175 1 599-606 2005
2. Higgins JP. Bernstein MB. Hodge JW. Enhancing immune responses to tumor-Associated antigens. Cancer Biol. Ther.8 15 1440-1449 2009
3. Paschen A. Eichmuller S Schadendorf D. Identification of tumor antigens and T-cell epitopes and its clinical application. Cancer Immunol. Immunother 53 3 196-203 2004
4. Viatte S. Alves PM. Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: Advantages and hurdles. Immunol. Cell Biol 84 3 318-330 2006
5. Kalinski P. Urban J. Narang R. Berk E. Wieckowski E. Muthuswamy R. Dendritic cell-based therapeutic cancer vaccines: What we have and what we need. Future Oncol.5 3 379-390 2009
6. Mandic M, Castelli F, Janjic B et al. One NY ESO 1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY ESO 1-expressing melanoma.J. Immunol.174(3), 1751-1759 (2005
7. Webb AI, Dunstone MA, Chen W et al. Functional and structural characteristics of NY ESO 1-related HLA A2- restricted epitopes and the design of a novel immunogenic analogue.J. Biol. Chem.279(22), 23438-23446 (2004
8. Bownds S, Tong-On P, Rosenberg SA, Parkhurst M. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY ESO 1 modified at the carboxy-Terminus to enhance HLA-A2.1 binding affinity and stability in solution.J. Immunother.24(1), 1-9 (2001
9. Zeng G, Aldridge ME, Wang Y et al. Dominant B cell epitope from NY ESO 1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker. Int.J. Cancer 114(2), 268-273 (2005
10. Chengalvala MV, Bhat RA, Bhat BM, Vernon SK, Lubeck MD. Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Vaccine 17(9-10), 1035-1041 (1999
11. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88- dependent signaling pathway. Nat. Immunol.3(2), 196-200 (2002
12. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu. Rev. Immunol.18, 767-811 (2000
13. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol.9, 271-296 (1991
14. Guy B. The perfect mix: Recent progress in adjuvant research. Nat. Rev. Microbiol.5(7), 505-517 (2007
15. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33(4), 464-478 (2010
16. Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities.J. Immunol.171(7), 3385-3393 (2003
17. Osada Y, Kumagai T, Hato M et al. Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. Vaccine 23(21), 2813-2819 (2005
18. Santini SM, Lapenta C, Santodonato L, D'agostino G, Belardelli F, Ferrantini M. IFN alpha in the generation of dendritic cells for cancer immunotherapy. Handb. Exp. Pharmacol.(188), 295-317 (2009
19. Sims JE, Smith DE. The IL 1 family: Regulators of immunity. Nat. Rev. Immunol.10(2), 89-102 (2010
20. Tagliabue A, Boraschi D. Cytokines as vaccine adjuvants: Interleukin 1 and its synthetic peptide 163-171. Vaccine 11(5), 594-595 (1993
21. Yang JM, Wang HJ, Du L et al. Screening and identification of novel B cell epitopes in human heparanase and their anti-invasion property for hepatocellular carcinoma. Cancer Immunol. Immunother.58(9), 1387-1396 (2009
22. Mosley B, Dower SK, Gillis S, Cosman D. Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1a and 1b. Proc. Natl Acad. Sci. USA 84(13), 4572-4576 (1987
23. Rosenwasser LJ, Webb AC, Clark BD et al. Expression of biologically active human interleukin 1 subpeptides by transfected simian COS cells. Proc. Natl Acad. Sci. USA 83(14), 5243-5246 (1986
24. Schaecher KE, Goust JM, Banik NL. The effects of calpain inhibition upon IL 2 and CD25 expression in human peripheral blood mononuclear cells.J. Neuroimmunol.119(2), 333-342 (2001
25. Tacken PJ, Ginter W, Berod L et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 118(15), 4111-4119 (2011
26. Amigorena S, Bonnerot C. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin. Immunol.11(6), 385-390 (1999
27. Regnault A, Lankar D, Lacabanne V et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization.J. Exp. Med.189(2), 371-380 (1999
28. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B et al. Antigen-Antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo.J. Immunol.168(5), 2240-2246 (2002
29. Akiyama K, Ebihara S, Yada A et al. Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells.J. Immunol.170(4), 1641-1648 (2003
30. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells.J. Exp. Med.195(12), 1653-1659 (2002
31. Woof JM, Burton DR. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol.4(2), 89-99 (2004
32. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393(6684), 478-480 (1998
33. Getahun A, Dahlstrom J, Wernersson S, Heyman B. IgG2a-mediated enhancement of antibody and T cell responses and its relation to inhibitory and activating Fc gamma receptors.J. Immunol.172(9), 5269-5276 (2004
34. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int.J. Pept. Protein Res.35(3), 161-214 (1990
35. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem.34(2), 595-598 (1970
36. Mercadal M, Domingo JC, Petriz J, Garcia J, De Madariaga MA. Preparation of immunoliposomes bearing poly(ethylene glycol)-coupled monoclonal antibody linked via a cleavable disulfide bond for ex vivo applications. Biochim. Biophys. Acta 1509(1-2), 299-310 (2000
37. Benmohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis.2(7), 425-431 (2002
38. Cruz LJ, Rueda F, Cordobilla B et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol. Pharm.8(1), 104-116 (2011
39. Jurk M, Heil F, Vollmer J et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol.3(6), 499 (2002
40. Forni G, Musso T, Jemma C, Boraschi D, Tagliabue A, Giovarelli M. Lymphokine-Activated tumor inhibition in mice. Ability of a nonapeptide of the human IL 1 beta to recruit antitumor reactivity in recipient mice.J. Immunol.142(2), 712-718 (1989
41. Tacken PJ, Zeelenberg IS, Cruz LJ et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118(26), 6836-6844 (2011
42. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50(3-4), 213-219 (1999
43. Lundegaard C, Nielsen M, Lund O. The validity of predicted T-cell epitopes. Trends Biotechnol.24(12), 537-538 (2006
44. Lundegaard C, Lund O, Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24(11), 1397-1398 (2008
45. Turk D, Guncar G. Lysosomal cysteine proteases (cathepsins): Promising drug targets. Acta Crystallogr.D. Biol. Crystallogr.59(Pt 2), 203-213 (2003
46. Alving CR, Swartz GM, Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: Implications for atherosclerosis and autoimmunity. Crit. Rev. Immunol.10(5), 441-453 (1991
47. Chikh G, Schutze-Redelmeier MP. Liposomal delivery of CTL epitopes to dendritic cells. Biosci. Rep.22(2), 339-353 (2002
48. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: Clinical results. Adv. Exp. Med. Biol.667, 111-123 (2010
49. Kim D, Kwon S, Rhee JW et al. Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol.12, 29 (2011
50. Fifis T, Mottram P, Bogdanoska V, Hanley J, Plebanski M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 23(2), 258-266 (2004
51. Boraschi D, Nencioni L, Villa L et al. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1b.J. Exp. Med.168(2), 675-686 (1988
52. Xu X, Zhang D, Sun W et al.A Schistosoma japonicum chimeric protein with a novel adjuvant induced a polarized Th1 immune response and protection against liver egg burdens. BMC Infect. Dis.9, 54 (2009
53. Zhang R, Yoshida A, Kumagai T et al. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect. Immun.69(1), 386-391 (2001
54. Boscardin SB, Hafalla JC, Masilamani RF et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses.J. Exp. Med.203(3), 599-606 (2006
55. Lin Y, Zhang L, Cai AX et al. Effective post-Transplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.J. Clin. Invest.121(4), 1574-1584 (2011
56. Yanez R, Barrios Y, Ruiz E, Cabrera R, Diaz-Espada F. Anti-idiotypic immunotherapy in follicular lymphoma patients: Results of a long follow-up study.J. Immunother.31(3), 310-312 (2008.